Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low- or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.
Written by:
Greene DE, Mayadev JS, Valicenti RK Are you the author?
Lieutenant Commander, 4501 X st, Radiation Oncology, Sacramento, CA 95817, USA
Reference: Ther Adv Urol. 2012 Jun;4(3):113-24.
doi: 10.1177/1756287212442977
PubMed Abstract
PMID: 22654963